Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

551 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PLX4032: does it keep its promise for metastatic melanoma treatment?
Livingstone E, Zimmer L, Piel S, Schadendorf D. Livingstone E, et al. Among authors: zimmer l. Expert Opin Investig Drugs. 2010 Nov;19(11):1439-49. doi: 10.1517/13543784.2010.527945. Epub 2010 Oct 14. Expert Opin Investig Drugs. 2010. PMID: 20942773 Review.
Current advances and perspectives in the treatment of advanced melanoma.
Livingstone E, Zimmer L, Vaubel J, Schadendorf D. Livingstone E, et al. Among authors: zimmer l. J Dtsch Dermatol Ges. 2012 May;10(5):319-25. doi: 10.1111/j.1610-0387.2012.07895.x. Epub 2012 Mar 20. J Dtsch Dermatol Ges. 2012. PMID: 22432863 Free article. Review.
Side effects of systemic oncological therapies in dermatology.
Zimmer L, Vaubel J, Livingstone E, Schadendorf D. Zimmer L, et al. J Dtsch Dermatol Ges. 2012 Jul;10(7):475-86. doi: 10.1111/j.1610-0387.2012.07942.x. Epub 2012 May 9. J Dtsch Dermatol Ges. 2012. PMID: 22571234 Free article. Review. English, German.
Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition.
Zimmer L, Hillen U, Livingstone E, Lacouture ME, Busam K, Carvajal RD, Egberts F, Hauschild A, Kashani-Sabet M, Goldinger SM, Dummer R, Long GV, McArthur G, Scherag A, Sucker A, Schadendorf D. Zimmer L, et al. J Clin Oncol. 2012 Jul 1;30(19):2375-83. doi: 10.1200/JCO.2011.41.1660. Epub 2012 May 21. J Clin Oncol. 2012. PMID: 22614973 Free PMC article.
Conjunctival melanomas harbor BRAF and NRAS mutations--response.
Griewank KG, Westekemper H, Schilling B, Livingstone E, Schimming T, Sucker A, Hillen U, Steuhl KP, Zimmer L, Schadendorf D. Griewank KG, et al. Among authors: zimmer l. Clin Cancer Res. 2013 Nov 15;19(22):6331-2. doi: 10.1158/1078-0432.CCR-13-2368. Epub 2013 Oct 29. Clin Cancer Res. 2013. PMID: 24170549 No abstract available.
Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
Goldinger SM, Zimmer L, Schulz C, Ugurel S, Hoeller C, Kaehler KC, Schadendorf D, Hassel JC, Becker J, Hauschild A, Dummer R; Dermatology Cooperative Oncology Group (DeCOG). Goldinger SM, et al. Among authors: zimmer l. Eur J Cancer. 2014 Jan;50(2):406-10. doi: 10.1016/j.ejca.2013.09.014. Epub 2013 Oct 29. Eur J Cancer. 2014. PMID: 24183461
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.
Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, Place CS, Taylor-Weiner A, Whittaker S, Kryukov GV, Hodis E, Rosenberg M, McKenna A, Cibulskis K, Farlow D, Zimmer L, Hillen U, Gutzmer R, Goldinger SM, Ugurel S, Gogas HJ, Egberts F, Berking C, Trefzer U, Loquai C, Weide B, Hassel JC, Gabriel SB, Carter SL, Getz G, Garraway LA, Schadendorf D; Dermatologic Cooperative Oncology Group of Germany (DeCOG). Van Allen EM, et al. Among authors: zimmer l. Cancer Discov. 2014 Jan;4(1):94-109. doi: 10.1158/2159-8290.CD-13-0617. Epub 2013 Nov 21. Cancer Discov. 2014. PMID: 24265153 Free PMC article.
551 results